CO5251398A1 - Compuestos calciliticos - Google Patents
Compuestos calciliticosInfo
- Publication number
- CO5251398A1 CO5251398A1 CO01005224A CO01005224A CO5251398A1 CO 5251398 A1 CO5251398 A1 CO 5251398A1 CO 01005224 A CO01005224 A CO 01005224A CO 01005224 A CO01005224 A CO 01005224A CO 5251398 A1 CO5251398 A1 CO 5251398A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- ethyl
- group
- indan
- aryl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/50—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/34—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C251/48—Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
- C07C69/616—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety polycyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Silicates, Zeolites, And Molecular Sieves (AREA)
Abstract
Un compuesto según la Fórmula (I) siguiente:<EMI FILE="01005224_1" ID="1" IMF=JPEG >en la que: A es un arilo o arilo condensado, dihidro-o tetrahidro-arilo condensado, heteroarilo o heteroarilo condensado, dihidro-otetrahidro-heteroarilo condensado, no sustituido o sustituidocon cualquier sustituyente seleccionado del grupo formado por OH, halógeno, alquilo C1-4, aIcoxi C1-4, cicloalquilo C3-6, CF3, OCF3, CN y NO2; X1 y X5 se seleccionan independientemente del grupo formado por H, halógeno, CN y NO2, siempre que o bien X1 o X5 sea H; X2, X3 y X4 se seleccionan del grupo formado por H, halógeno, O-alquilo C1-4 y .J-K, donde:J es un enlace covalente, alquileno, O-alquileno o alquenileno, y K se selecciona del grupo formado por CO2R5, CONR4RAND#394, OH, NR4RAND#394 y CN; R4 y RAND#394 son independientemente H, alquilo, arilo o heteroarilo; R5 es H, alquilo, alquil-(O-alquil)m-O-alquilo; n es un número entero de 0 a 4; y m es un número entero de 1 a 3, o una sal farmacéuticamente aceptable del mismo. 1 Un compuesto seleccionado del grupo constituidopor: 2-Indan-2-il-1,1 -dimetil-etilamina; Éster metílico de ácido indan-2-il-acético; 1 -Indan-2-il-2-metil-propan-2-ol; N-(2-indan-2-il-1,1-dimetil-etil)-acetamida; (R)-4-ciano-3-(oxiranilmetoxi)-bencenopropionato de etilo; 4-formil-3-hidroxibencenopropionato de etilo; 3-hidroxi-4-[(hidroxiimino)-metil]-bencenopropionato de etilo; 3-acetoxi-4-cianobencenopropionato de etilo; y 4-ciano-3-hidroxibencenopropionato de etilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17768300P | 2000-01-24 | 2000-01-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5251398A1 true CO5251398A1 (es) | 2003-02-28 |
Family
ID=22649559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO01005224A CO5251398A1 (es) | 2000-01-24 | 2001-01-24 | Compuestos calciliticos |
Country Status (31)
| Country | Link |
|---|---|
| EP (2) | EP1254106B1 (es) |
| JP (1) | JP2003520265A (es) |
| KR (1) | KR20020073179A (es) |
| CN (1) | CN1396906A (es) |
| AP (1) | AP2002002547A0 (es) |
| AR (1) | AR030684A1 (es) |
| AT (1) | ATE423762T1 (es) |
| AU (1) | AU764746B2 (es) |
| BG (1) | BG106942A (es) |
| BR (1) | BR0107592A (es) |
| CA (1) | CA2397802A1 (es) |
| CO (1) | CO5251398A1 (es) |
| DE (1) | DE60137755D1 (es) |
| DZ (1) | DZ3284A1 (es) |
| EA (1) | EA200200798A1 (es) |
| ES (1) | ES2322641T3 (es) |
| HK (1) | HK1051356A1 (es) |
| HU (1) | HUP0204106A3 (es) |
| IL (1) | IL150398A0 (es) |
| MA (1) | MA25651A1 (es) |
| MX (1) | MXPA02007173A (es) |
| MY (1) | MY159417A (es) |
| NO (1) | NO20023508D0 (es) |
| NZ (1) | NZ519480A (es) |
| OA (1) | OA12163A (es) |
| PE (1) | PE20011062A1 (es) |
| PL (1) | PL356808A1 (es) |
| SK (1) | SK10742002A3 (es) |
| UY (1) | UY26556A1 (es) |
| WO (1) | WO2001053254A1 (es) |
| ZA (1) | ZA200205832B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1308436B1 (en) * | 2000-08-11 | 2008-10-15 | Japan Tobacco Inc. | Calcium receptor antagonists |
| WO2002034204A2 (en) * | 2000-10-25 | 2002-05-02 | Smithkline Beecham Corporation | Calcilytic compounds |
| UY28089A1 (es) | 2002-11-26 | 2004-06-30 | Smithkline Beecham Corp | Compuestos calciliticos |
| MXPA05007609A (es) | 2003-04-23 | 2005-09-30 | Japan Tobacco Inc | Antagonista de un receptor sensible al calcio. |
| WO2005077892A1 (en) * | 2004-02-06 | 2005-08-25 | Smithkline Beecham Corporation | Calcilytic compounds |
| JP2007522148A (ja) * | 2004-02-06 | 2007-08-09 | スミスクライン・ビーチャム・コーポレイション | カルシウム受容体アンタゴニスト化合物 |
| PT2292592E (pt) | 2008-06-05 | 2012-11-12 | Asahi Kasei Pharma Corp | Composto de sulfonamida e sua aplicação |
| CN102307847A (zh) | 2008-12-24 | 2012-01-04 | 第一三共株式会社 | 茚满基化合物 |
| CN107417594B (zh) * | 2017-05-08 | 2020-03-27 | 凯莱英医药集团（天津）股份有限公司 | 一种酰胺醇解的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2530613A1 (de) * | 1974-11-01 | 1976-05-06 | Haessle Ab | Aminderivate, verfahren zu deren herstellung und sie enthaltende arzneimittel |
| US4234595A (en) * | 1977-07-13 | 1980-11-18 | Mead Johnson & Company | 3-Indolyl-tertiary butylaminopropanols |
| FR2533210A1 (fr) * | 1982-09-17 | 1984-03-23 | Lyon I Universite Claude | Edulcorants de synthese |
| DD298506A5 (de) * | 1988-12-30 | 1992-02-27 | Ernst-Moritz-Arndt-Universitaet Greifswald,De | Verfahren zur herstellung halogensubstituierter 1-phenoxy-3-alkylamino-propan-2-ole |
| DE4040186A1 (de) * | 1989-12-20 | 1991-06-27 | Hoechst Ag | Hypoglykaemisch aktive propandiolaminderivate mit insulin-aehnlicher wirkung und deren verwendung, neue propandiolaminderivate, diese substanzen enthaltende pharmazeutische zubereitungen und ihre verwendung zur behandlung von krankheiten |
| EP0901459B1 (en) * | 1996-04-09 | 2005-06-29 | Nps Pharmaceuticals, Inc. | Calcilytic compounds |
| UY24949A1 (es) * | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
| PE20000415A1 (es) * | 1998-04-08 | 2000-05-21 | Smithkline Beecham Corp | Compuestos calciliticos |
| AR014975A1 (es) * | 1998-04-08 | 2001-04-11 | Nps Pharma Inc | Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento |
| ECSP003590A (es) * | 1999-07-31 | 2002-02-25 | Smithkline Beecham Corp | Compuestos calcioliticos |
-
2001
- 2001-01-22 AR ARP010100268A patent/AR030684A1/es not_active Application Discontinuation
- 2001-01-22 MY MYPI20010288A patent/MY159417A/en unknown
- 2001-01-23 PE PE2001000069A patent/PE20011062A1/es not_active Application Discontinuation
- 2001-01-24 EP EP01910349A patent/EP1254106B1/en not_active Expired - Lifetime
- 2001-01-24 CA CA002397802A patent/CA2397802A1/en not_active Abandoned
- 2001-01-24 AP APAP/P/2002/002547A patent/AP2002002547A0/en unknown
- 2001-01-24 EP EP09002553A patent/EP2141146A1/en not_active Withdrawn
- 2001-01-24 BR BR0107592-6A patent/BR0107592A/pt not_active IP Right Cessation
- 2001-01-24 KR KR1020027009415A patent/KR20020073179A/ko not_active Application Discontinuation
- 2001-01-24 DE DE60137755T patent/DE60137755D1/de not_active Expired - Lifetime
- 2001-01-24 WO PCT/US2001/002402 patent/WO2001053254A1/en active IP Right Grant
- 2001-01-24 OA OA1200200218A patent/OA12163A/en unknown
- 2001-01-24 UY UY26556A patent/UY26556A1/es not_active Application Discontinuation
- 2001-01-24 IL IL15039801A patent/IL150398A0/xx unknown
- 2001-01-24 HU HU0204106A patent/HUP0204106A3/hu unknown
- 2001-01-24 AU AU37966/01A patent/AU764746B2/en not_active Expired
- 2001-01-24 MX MXPA02007173A patent/MXPA02007173A/es unknown
- 2001-01-24 EA EA200200798A patent/EA200200798A1/ru unknown
- 2001-01-24 PL PL01356808A patent/PL356808A1/xx not_active Application Discontinuation
- 2001-01-24 CO CO01005224A patent/CO5251398A1/es not_active Application Discontinuation
- 2001-01-24 ES ES01910349T patent/ES2322641T3/es not_active Expired - Lifetime
- 2001-01-24 SK SK1074-2002A patent/SK10742002A3/sk not_active Application Discontinuation
- 2001-01-24 NZ NZ519480A patent/NZ519480A/en not_active IP Right Cessation
- 2001-01-24 AT AT01910349T patent/ATE423762T1/de not_active IP Right Cessation
- 2001-01-24 CN CN01804024A patent/CN1396906A/zh active Pending
- 2001-01-24 DZ DZ013284A patent/DZ3284A1/fr active
- 2001-01-24 JP JP2001553259A patent/JP2003520265A/ja not_active Withdrawn
-
2002
- 2002-07-22 ZA ZA200205832A patent/ZA200205832B/en unknown
- 2002-07-23 NO NO20023508A patent/NO20023508D0/no unknown
- 2002-07-23 BG BG106942A patent/BG106942A/bg unknown
- 2002-07-24 MA MA26743A patent/MA25651A1/fr unknown
-
2003
- 2003-03-25 HK HK03102155.4A patent/HK1051356A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5280060A1 (es) | Aminoacidos biciclicos como agentes farmaceuticos | |
| EA200300023A1 (ru) | 3'-ПРОЛЕКАРСТВА 2'-ДЕЗОКСИ-β-L-НУКЛЕОЗИДОВ | |
| EA200500610A1 (ru) | Композиция для лечения инфекции, вызываемой вирусами семейств flaviviridae | |
| IS8448A (is) | Lifrarbólgu C-veirutálmar | |
| CO5251404A1 (es) | Compuestos antibioticos de azalida | |
| CO5251398A1 (es) | Compuestos calciliticos | |
| MX2010008468A (es) | Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante. | |
| DE602005026554D1 (de) | Copolymerisierbare azoverbindungen und artikel damit | |
| CO5930056A1 (es) | Composiciones con ciclopopenos | |
| EP3321263A3 (en) | Compounds for preparing hepatitis c virus inhibitors | |
| EA200800932A1 (ru) | Модифицированные 4`-нуклеозиды в качестве противовирусных агентов | |
| CY1113038T1 (el) | Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινου | |
| CA2494613A1 (en) | Pyrrolidinedione substituted piperidine-phthalazones as pde4 inhibitors | |
| CL2008003431A1 (es) | Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih. | |
| ATE407155T1 (de) | Pyridin-imin polymerisationskatalysator | |
| EA200900156A1 (ru) | Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе | |
| RU2695274C3 (ru) | Новые композиции и способы их стабилизации | |
| JP2007534743A5 (es) | ||
| CO5231152A1 (es) | Formulaciones plaguicidas que contienen tensoactivos de piliarilfenolfosfatoester alcoxilado y tensoactivo de lignosulfonato alcoxilado | |
| TR200003414T2 (tr) | Anti-viral terkipler | |
| WO2001055131A3 (en) | Prodigiosin-derivatives as neoplastic and anti-viral agents | |
| CA2458318A1 (en) | Wortmannin analogs and methods of using same | |
| CO5261594A1 (es) | Inhibidores de myt1 cinasa | |
| EP1398306A3 (en) | A (1'R, 2'S, 5'R)-3-l-Menthoxyalkan-1-ol cooling sensate | |
| AR028040A1 (es) | Remocion de virus de celulas neoplasticas a partir de composiciones celulares mixtas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |